Pegavision Corporation (6491.TW)
TWD 335.5
(-3.59%)
TWD 335.5
(-3.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.87 Billion TWD | 26.09% |
| 2022 | 3.07 Billion TWD | 0.63% |
| 2021 | 3.05 Billion TWD | 67.91% |
| 2020 | 1.82 Billion TWD | 44.93% |
| 2019 | 1.25 Billion TWD | -41.3% |
| 2018 | 2.13 Billion TWD | 48.37% |
| 2017 | 1.44 Billion TWD | 105.43% |
| 2016 | 701.96 Million TWD | 3.51% |
| 2015 | 678.17 Million TWD | 3.51% |
| 2014 | 655.17 Million TWD | 34.77% |
| 2013 | 486.14 Million TWD | -25.8% |
| 2012 | 655.17 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.23 Billion TWD | 9.07% |
| 2024 Q3 | 3.85 Billion TWD | -14.13% |
| 2024 Q2 | 4.49 Billion TWD | 6.24% |
| 2023 Q3 | 3.02 Billion TWD | -10.06% |
| 2023 Q4 | 3.87 Billion TWD | 28.34% |
| 2023 Q1 | 3.8 Billion TWD | 23.76% |
| 2023 FY | 3.87 Billion TWD | 26.09% |
| 2023 Q2 | 3.35 Billion TWD | -11.74% |
| 2022 Q4 | 3.07 Billion TWD | 1.56% |
| 2022 Q1 | 3.6 Billion TWD | 17.93% |
| 2022 Q2 | 3.96 Billion TWD | 10.13% |
| 2022 FY | 3.07 Billion TWD | 0.63% |
| 2022 Q3 | 3.02 Billion TWD | -23.71% |
| 2021 Q2 | 2.94 Billion TWD | 37.1% |
| 2021 Q1 | 2.14 Billion TWD | 17.95% |
| 2021 Q3 | 3.16 Billion TWD | 7.41% |
| 2021 Q4 | 3.05 Billion TWD | -3.34% |
| 2021 FY | 3.05 Billion TWD | 67.91% |
| 2020 FY | 1.82 Billion TWD | 44.93% |
| 2020 Q4 | 1.82 Billion TWD | 14.64% |
| 2020 Q1 | 1.32 Billion TWD | 5.56% |
| 2020 Q2 | 1.43 Billion TWD | 8.5% |
| 2020 Q3 | 1.58 Billion TWD | 10.38% |
| 2019 Q1 | - TWD | -100.0% |
| 2019 FY | 1.25 Billion TWD | -41.3% |
| 2019 Q4 | 1.25 Billion TWD | -54.14% |
| 2019 Q3 | 2.73 Billion TWD | -4.39% |
| 2019 Q2 | 2.86 Billion TWD | 0.0% |
| 2018 Q2 | 2.38 Billion TWD | 0.0% |
| 2018 Q1 | - TWD | -100.0% |
| 2018 FY | 2.13 Billion TWD | 48.37% |
| 2018 Q4 | 2.13 Billion TWD | 0.0% |
| 2017 Q1 | 885.06 Million TWD | 26.08% |
| 2017 FY | 1.44 Billion TWD | 105.43% |
| 2017 Q3 | 1.44 Billion TWD | 62.93% |
| 2017 Q2 | 885.06 Million TWD | 0.0% |
| 2017 Q4 | 1.44 Billion TWD | 0.0% |
| 2016 FY | 701.96 Million TWD | 3.51% |
| 2016 Q4 | 701.96 Million TWD | 0.0% |
| 2016 Q3 | 701.96 Million TWD | 13.56% |
| 2016 Q1 | 618.14 Million TWD | -8.85% |
| 2016 Q2 | 618.14 Million TWD | 0.0% |
| 2015 Q4 | 678.17 Million TWD | 0.0% |
| 2015 Q2 | 752.61 Million TWD | 0.0% |
| 2015 FY | 678.17 Million TWD | 3.51% |
| 2015 Q3 | 678.17 Million TWD | -9.89% |
| 2015 Q1 | 752.61 Million TWD | 14.87% |
| 2014 Q1 | 493.48 Million TWD | 1.51% |
| 2014 Q2 | 493.48 Million TWD | 0.0% |
| 2014 Q3 | 655.17 Million TWD | 32.77% |
| 2014 Q4 | 655.17 Million TWD | 0.0% |
| 2014 FY | 655.17 Million TWD | 34.77% |
| 2013 Q4 | 486.14 Million TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 FY | 486.14 Million TWD | -25.8% |
| 2013 Q3 | 486.14 Million TWD | 0.0% |
| 2012 FY | 655.17 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 1.47 Billion TWD | -162.216% |
| Maxigen Biotech Inc. | 131.88 Million TWD | -2840.746% |
| SciVision Biotech Inc. | 533.66 Million TWD | -626.738% |
| Bionime Corporation | 3.3 Billion TWD | -17.264% |
| Visco Vision Inc. | 1.74 Billion TWD | -122.696% |